Action Iterum Therapeutics (ITRM)

Iterum Therapeutics plc (ITRM) is a small, clinical‑stage pharmaceutical company focused on developing anti‑infective treatments to address bacterial infections. With a market capitalisation of roughly $35 million, Iterum is a micro‑cap where value often depends on clinical trial results, regulatory progress and access to funding. The company’s prospects can be materially affected by binary events such as trial readouts or approval decisions, and it may rely on partnerships or capital raises to advance programmes. Shares can be thinly traded and prone to volatility, so liquidity and dilution risks are important considerations. This summary is for general educational purposes and not personalised investment advice — investors should review the company’s latest filings, monitor operational updates and consult a regulated financial adviser before making investment decisions.